Department of Pediatrics, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Nephrol Dial Transplant. 2013 Dec;28(12):2993-3003. doi: 10.1093/ndt/gft350. Epub 2013 Sep 15.
Previous studies have identified significant associations between the development of idiopathic focal segmental glomerulosclerosis (FSGS) and MYH9 encoding nonmuscle myosin heavy chain-IIA (NMMHC-IIA). However, these studies focused only on the linkage of MYH9 polymorphisms and development of FSGS. There have been no reports on pathological changes of NMMHC-IIA in human glomerular diseases. Here we report on the precise localization of NMMHC-IIA in podocytes and changes in NMMHC-IIA expression in pathological states in rats and humans.
Immunocytochemical (immunofluorescence and immunoelectron microscopy) studies were performed to determine the precise localization of NMMHC-IIA. Expression levels of NMMHC-IIA were investigated in puromycin aminonucleoside (PAN)-treated rats; and expression levels of NMMHC-IIA and other podocyte-related proteins were investigated in glomeruli of patients with idiopathic FSGS and other heavy proteinuric glomerular diseases.
NMMHC-IIA was located primarily at the cell body and primary processes of podocytes; this localization is distinct from other podocyte-related molecules causing hereditary FSGS. In PAN-treated rat kidneys, expression levels of NMMHC-IIA in podocytes decreased. Immunohistochemical analysis revealed that expression levels of NMMHC-IIA markedly decreased in idiopathic nephrotic syndrome, especially FSGS, whereas it did not change in other chronic glomerulonephritis showing apparent proteinuria. Changes in NMMHC-IIA expression were observed in glomeruli where expression of nephrin and synaptopodin was maintained.
Considering previous genome-wide association studies and development of FSGS in patients with MYH9 mutations, the characteristic localization of NMMHC-IIA and the specific decrease in NMMHC-IIA expression in idiopathic nephrotic syndrome, especially FSGS, suggest the important role of NMMHC-IIA in the development of FSGS.
先前的研究已经确定特发性局灶节段性肾小球硬化症(FSGS)的发展与编码非肌肉肌球蛋白重链-IIA(NMMHC-IIA)的 MYH9 之间存在显著关联。然而,这些研究仅关注 MYH9 多态性与 FSGS 发展之间的关联。目前尚无关于 NMMHC-IIA 在人类肾小球疾病中的病理变化的报道。在这里,我们报告了 NMMHC-IIA 在足细胞中的精确定位以及在大鼠和人类病理状态下 NMMHC-IIA 表达的变化。
进行免疫细胞化学(免疫荧光和免疫电子显微镜)研究以确定 NMMHC-IIA 的精确定位。研究了嘌呤霉素氨基核苷(PAN)处理的大鼠中 NMMHC-IIA 的表达水平;并研究了特发性 FSGS 和其他大量蛋白尿性肾小球疾病患者肾小球中 NMMHC-IIA 和其他足细胞相关蛋白的表达水平。
NMMHC-IIA 主要位于足细胞的细胞体和初级突起中;这种定位与导致遗传性 FSGS 的其他足细胞相关分子不同。在 PAN 处理的大鼠肾脏中,足细胞中 NMMHC-IIA 的表达水平下降。免疫组织化学分析显示,特发性肾病综合征,特别是 FSGS 中 NMMHC-IIA 的表达明显降低,而在其他表现出明显蛋白尿的慢性肾小球肾炎中则没有变化。在保持nephrin 和 synaptopodin 表达的肾小球中观察到 NMMHC-IIA 表达的变化。
考虑到先前的全基因组关联研究和 MYH9 突变患者 FSGS 的发展,NMMHC-IIA 的特征性定位以及特发性肾病综合征,特别是 FSGS 中 NMMHC-IIA 表达的特异性下降,表明 NMMHC-IIA 在 FSGS 的发展中具有重要作用。